Engineering exhaustion-resistance CD19 CAR T cells to address translational barriers for the treatment of cancer and autoimmune disease
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability.
Appeared: Sunday, November 15. Science Advances. Peer-reviewed journal.